DNTH
Price
$42.13
Change
+$0.50 (+1.20%)
Updated
Dec 12 closing price
Capitalization
1.81B
Intraday BUY SELL Signals
VRDN
Price
$32.31
Change
-$0.26 (-0.80%)
Updated
Dec 12 closing price
Capitalization
3.08B
81 days until earnings call
Intraday BUY SELL Signals
Interact to see
Advertisement

DNTH vs VRDN

Header iconDNTH vs VRDN Comparison
Open Charts DNTH vs VRDNBanner chart's image
Dianthus Therapeutics
Price$42.13
Change+$0.50 (+1.20%)
Volume$520.2K
Capitalization1.81B
Viridian Therapeutics
Price$32.31
Change-$0.26 (-0.80%)
Volume$943.61K
Capitalization3.08B
DNTH vs VRDN Comparison Chart in %
DNTH
Daily Signal:
Gain/Loss:
VRDN
Daily Signal:
Gain/Loss:
View a ticker or compare two or three
VS
DNTH vs. VRDN commentary
Dec 14, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is DNTH is a StrongBuy and VRDN is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Dec 14, 2025
Stock price -- (DNTH: $41.63 vs. VRDN: $32.57)
Brand notoriety: DNTH and VRDN are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: DNTH: 116% vs. VRDN: 52%
Market capitalization -- DNTH: $1.81B vs. VRDN: $3.08B
DNTH [@Biotechnology] is valued at $1.81B. VRDN’s [@Biotechnology] market capitalization is $3.08B. The market cap for tickers in the [@Biotechnology] industry ranges from $114.69B to $0. The average market capitalization across the [@Biotechnology] industry is $2.21B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

DNTH’s FA Score shows that 1 FA rating(s) are green whileVRDN’s FA Score has 0 green FA rating(s).

  • DNTH’s FA Score: 1 green, 4 red.
  • VRDN’s FA Score: 0 green, 5 red.
According to our system of comparison, DNTH is a better buy in the long-term than VRDN.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

DNTH’s TA Score shows that 4 TA indicator(s) are bullish while VRDN’s TA Score has 3 bullish TA indicator(s).

  • DNTH’s TA Score: 4 bullish, 6 bearish.
  • VRDN’s TA Score: 3 bullish, 5 bearish.
According to our system of comparison, both DNTH and VRDN are a bad buy in the short-term.

Price Growth

DNTH (@Biotechnology) experienced а -6.89% price change this week, while VRDN (@Biotechnology) price change was +0.34% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.68%. For the same industry, the average monthly price growth was +4.10%, and the average quarterly price growth was +64.61%.

Reported Earning Dates

VRDN is expected to report earnings on Mar 05, 2026.

Industries' Descriptions

@Biotechnology (+0.68% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
VRDN($3.08B) has a higher market cap than DNTH($1.81B). DNTH YTD gains are higher at: 90.963 vs. VRDN (69.901). DNTH has higher annual earnings (EBITDA): -139.9M vs. VRDN (-298.48M). VRDN has more cash in the bank: 491M vs. DNTH (403M). DNTH has less debt than VRDN: DNTH (1.29M) vs VRDN (21.6M). VRDN has higher revenues than DNTH: VRDN (70.8M) vs DNTH (3.08M).
DNTHVRDNDNTH / VRDN
Capitalization1.81B3.08B59%
EBITDA-139.9M-298.48M47%
Gain YTD90.96369.901130%
P/E Ratio3.24N/A-
Revenue3.08M70.8M4%
Total Cash403M491M82%
Total Debt1.29M21.6M6%
FUNDAMENTALS RATINGS
DNTH vs VRDN: Fundamental Ratings
DNTH
VRDN
OUTLOOK RATING
1..100
6782
VALUATION
overvalued / fair valued / undervalued
1..100
66
Overvalued
52
Fair valued
PROFIT vs RISK RATING
1..100
2260
SMR RATING
1..100
9698
PRICE GROWTH RATING
1..100
3736
P/E GROWTH RATING
1..100
61100
SEASONALITY SCORE
1..100
5050

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

VRDN's Valuation (52) in the Biotechnology industry is in the same range as DNTH (66) in the null industry. This means that VRDN’s stock grew similarly to DNTH’s over the last 12 months.

DNTH's Profit vs Risk Rating (22) in the null industry is somewhat better than the same rating for VRDN (60) in the Biotechnology industry. This means that DNTH’s stock grew somewhat faster than VRDN’s over the last 12 months.

DNTH's SMR Rating (96) in the null industry is in the same range as VRDN (98) in the Biotechnology industry. This means that DNTH’s stock grew similarly to VRDN’s over the last 12 months.

VRDN's Price Growth Rating (36) in the Biotechnology industry is in the same range as DNTH (37) in the null industry. This means that VRDN’s stock grew similarly to DNTH’s over the last 12 months.

DNTH's P/E Growth Rating (61) in the null industry is somewhat better than the same rating for VRDN (100) in the Biotechnology industry. This means that DNTH’s stock grew somewhat faster than VRDN’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
DNTHVRDN
RSI
ODDS (%)
Bearish Trend 4 days ago
85%
Bearish Trend 4 days ago
77%
Stochastic
ODDS (%)
Bearish Trend 4 days ago
84%
Bearish Trend 4 days ago
83%
Momentum
ODDS (%)
Bearish Trend 4 days ago
84%
Bullish Trend 4 days ago
76%
MACD
ODDS (%)
Bearish Trend 4 days ago
90%
Bearish Trend 4 days ago
82%
TrendWeek
ODDS (%)
Bearish Trend 4 days ago
88%
Bullish Trend 4 days ago
82%
TrendMonth
ODDS (%)
Bullish Trend 4 days ago
80%
Bullish Trend 4 days ago
83%
Advances
ODDS (%)
Bullish Trend 11 days ago
80%
Bullish Trend 11 days ago
81%
Declines
ODDS (%)
Bearish Trend 6 days ago
87%
Bearish Trend 6 days ago
84%
BollingerBands
ODDS (%)
Bearish Trend 4 days ago
89%
Bearish Trend 4 days ago
83%
Aroon
ODDS (%)
Bullish Trend 4 days ago
83%
Bullish Trend 4 days ago
87%
View a ticker or compare two or three
Interact to see
Advertisement
DNTH
Daily Signal:
Gain/Loss:
VRDN
Daily Signal:
Gain/Loss:
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PFPFX54.730.53
+0.98%
Poplar Forest Partners A
EITMX126.910.34
+0.27%
Eaton Vance Tx-Mgd Growth 1.1 I
SQBIX15.330.04
+0.26%
X-Square Balanced Fund, LLC Instl
FINSX48.78N/A
N/A
Fidelity Advisor New Insights I
OAIEX15.36-0.05
-0.32%
Optimum International A

DNTH and

Correlation & Price change

A.I.dvisor indicates that over the last year, DNTH has been loosely correlated with RVMD. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if DNTH jumps, then RVMD could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To DNTH
1D Price
Change %
DNTH100%
-4.47%
RVMD - DNTH
48%
Loosely correlated
+0.81%
CGON - DNTH
46%
Loosely correlated
-0.31%
SYRE - DNTH
45%
Loosely correlated
-0.87%
VRDN - DNTH
45%
Loosely correlated
-0.09%
XNCR - DNTH
45%
Loosely correlated
-0.58%
More

VRDN and

Correlation & Price change

A.I.dvisor indicates that over the last year, VRDN has been loosely correlated with NUVL. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if VRDN jumps, then NUVL could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To VRDN
1D Price
Change %
VRDN100%
-0.09%
NUVL - VRDN
56%
Loosely correlated
+0.16%
XNCR - VRDN
54%
Loosely correlated
-0.58%
CLDX - VRDN
53%
Loosely correlated
-0.89%
SYRE - VRDN
52%
Loosely correlated
-0.87%
CRNX - VRDN
50%
Loosely correlated
+2.60%
More